Synergies Between Health Care and Insurance Drive Scalable Growth AI Innovations Fuel Continued Success SHANGHAI and HONG KONG, March 12, 2025 /PRNewswire/ — Ping An Healthcare and Technology Company Limited (“Ping An Good Doctor“, “Ping An Health” or “the Company”, Stock Code: 1833.HK) announced its 2024 annual results. With a strategic focus on its two core… Continue reading Ping An Health Reports First Full-Year Profit in 2024
Tag: M and A
Cal Poly Pomona’s Singelyn Graduate School of Business and Western University of Health Sciences Announce Innovative PharmD-MBA Pathway Program
POMONA, Calif., March 12, 2025 /PRNewswire/ — Cal Poly Pomona’s Singelyn Graduate School of Business (CPP SGSB) and the College of Pharmacy (COP) at Western University of Health Sciences (WesternU) are proud to announce an exciting new partnership to launch the dual assurance PharmD-MBA Program! This collaboration creates a seamless pathway for graduates of WesternU’s… Continue reading Cal Poly Pomona’s Singelyn Graduate School of Business and Western University of Health Sciences Announce Innovative PharmD-MBA Pathway Program
Statement from EBONY on the Passing of Ulysses “Junior” Bridgeman
LOUISVILLE, Ky., March 12, 2025 /PRNewswire/ — EBONY Media regrets to announce the passing of Ulysses “Junior” Bridgeman, father of our CEO, Eden Bridgeman. A renowned business leader, philanthropist, and former NBA player with the Milwaukee Bucks, Mr. Bridgeman’s legacy extends far beyond his successful athletic career. He exemplified excellence in both business and service… Continue reading Statement from EBONY on the Passing of Ulysses “Junior” Bridgeman
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to help improve patient access to high-quality biologic treatments[1]… Continue reading STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production. The new generator technology, developed internally by Telix’s IsoTherapeutics team, produces 212Pb via a sealed… Continue reading Telix Adds Lead-212 Isotope Production Capability
Safe and Green Development Corporation Updates Ex-Dividend Date For the Previously Announced Dividend
MIAMI, March 12, 2025 /PRNewswire/ — Safe and Green Development Corporation (NASDAQ: SGD) (“SG Devco” or the “Company”) today announced details regarding its previously declared stock dividend, including the confirmed date for trading on a stock dividend-adjusted basis. On March 5, 2025, SG Devco approved a stock dividend from its treasury shares, consisting of 0.05 shares… Continue reading Safe and Green Development Corporation Updates Ex-Dividend Date For the Previously Announced Dividend
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fluence Energy, Inc. of Class Action Lawsuit and Upcoming Deadlines – FLNC
NEW YORK, March 12, 2025 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address,… Continue reading INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Fluence Energy, Inc. of Class Action Lawsuit and Upcoming Deadlines – FLNC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SoundHound AI, Inc. – SOUN
NEW YORK, March 12, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SoundHound AI, Inc. (“SoundHound” or the “Company”) (NASDAQ: SOUN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether SoundHound and certain of its officers and/or directors have engaged in securities fraud or other… Continue reading INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SoundHound AI, Inc. – SOUN
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Grocery Outlet Holding Corp.
RADNOR, Pa., March 12, 2025 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Grocery Outlet Holding Corp. (“Grocery Outlet”) (NASDAQ: GO) on behalf of those who purchased or acquired Grocery Outlet securities between November 7, 2023, and May 7,… Continue reading Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Grocery Outlet Holding Corp.
Kewaunee Scientific Announces Amendment to Share Repurchase Program
STATESVILLE, N.C., March 12, 2025 /PRNewswire/ — Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced an amendment to its existing share repurchase program. On March 12, 2025, the Board of Directors of Kewaunee Scientific Corporation (the “Company”) amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023. The… Continue reading Kewaunee Scientific Announces Amendment to Share Repurchase Program